Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts

Clearside Biomedical, Inc. (NASDAQ:CLSDGet Rating) has been given a consensus rating of “Buy” by the seven analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $9.25.

CLSD has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Wednesday, April 13th. TheStreet raised shares of Clearside Biomedical from a “d” rating to a “c” rating in a research note on Friday, April 8th. JMP Securities decreased their price objective on shares of Clearside Biomedical from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Friday, March 11th. Wedbush reissued an “outperform” rating and issued a $9.00 price objective on shares of Clearside Biomedical in a research note on Friday, March 11th. Finally, StockNews.com assumed coverage on shares of Clearside Biomedical in a research note on Thursday, March 31st. They set a “hold” rating on the stock.

NASDAQ CLSD opened at $1.60 on Monday. Clearside Biomedical has a 1-year low of $1.31 and a 1-year high of $7.73. The company has a 50 day moving average of $1.98 and a 200-day moving average of $2.96. The company has a market cap of $96.24 million, a price-to-earnings ratio of -160.00 and a beta of 2.03.

Clearside Biomedical (NASDAQ:CLSDGet Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.22. The company had revenue of $25.69 million during the quarter, compared to the consensus estimate of $13.16 million. Clearside Biomedical had a net margin of 1.27% and a return on equity of 1.63%. During the same period in the previous year, the business earned ($0.14) earnings per share. Research analysts predict that Clearside Biomedical will post -0.25 earnings per share for the current year.

Large investors have recently modified their holdings of the company. Ameritas Investment Company LLC lifted its holdings in shares of Clearside Biomedical by 19.7% during the third quarter. Ameritas Investment Company LLC now owns 60,810 shares of the company’s stock worth $365,000 after purchasing an additional 10,000 shares during the period. Jump Financial LLC acquired a new position in shares of Clearside Biomedical during the third quarter worth $229,000. Assenagon Asset Management S.A. lifted its holdings in shares of Clearside Biomedical by 8,559.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,634,412 shares of the company’s stock worth $4,495,000 after purchasing an additional 1,615,538 shares during the period. Trexquant Investment LP acquired a new position in shares of Clearside Biomedical during the third quarter worth $263,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Clearside Biomedical by 200.0% during the third quarter. Cubist Systematic Strategies LLC now owns 79,967 shares of the company’s stock worth $480,000 after purchasing an additional 53,311 shares during the period. Institutional investors own 46.56% of the company’s stock.

Clearside Biomedical Company Profile (Get Rating)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Read More

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.